Longevity · Mitochondrial-derived peptide · Compounded 503A
MOTS-c: the peptide your mitochondria make when you exercise.
MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial genome — one of the first mitochondrial-derived peptides ever characterized. It activates AMPK, improves insulin sensitivity, and circulates at higher levels in active humans. It is one of the most cited exercise-mimetic peptides in the longevity literature.
What MOTS-c is
MOTS-c (Mitochondrial Open Reading frame of the Twelve S rRNA type-c) is a 16-amino-acid peptide encoded within the small ribosomal RNA gene of mitochondrial DNA. Discovered by Lee and colleagues at USC in 2015, it was one of the first 'mitochondrial-derived peptides' (MDPs) shown to act as a hormone-like signal between mitochondria and the nucleus.
Endogenous MOTS-c circulates in human plasma. Levels are higher in physically active humans and rise acutely with exercise. Levels decline with age and with insulin resistance — making MOTS-c one of the candidate biomarkers of metabolic aging.
Therapeutic MOTS-c is a synthetic version of the same peptide, administered subcutaneously. It is not FDA-approved. In the U.S. it is compounded by licensed 503A pharmacies and prescribed off-label as part of metabolic and longevity protocols.
How it works
MOTS-c's primary mechanism is AMPK activation. AMPK is the cell's master metabolic switch — when activated, it promotes glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and autophagy. It is the same pathway activated by metformin, exercise, and caloric restriction.
Beyond AMPK, MOTS-c translocates to the nucleus under metabolic stress and regulates expression of antioxidant and stress-response genes (including the NRF2 axis). This dual cytosolic + nuclear action is what makes it a 'mitokine' — a true mitochondria-to-nucleus signal.
In mice, MOTS-c administration improved insulin sensitivity, reduced diet-induced obesity, increased physical capacity in aged animals, and extended healthspan markers. Human data is earlier-stage but consistent with the animal pharmacology.
What patients use it for
Insulin sensitivity
MOTS-c is one of the most reproducible findings in the literature — improved insulin sensitivity and glucose uptake in skeletal muscle in both mice and early human work.
Mitochondrial biogenesis
AMPK activation drives PGC-1α and downstream mitochondrial biogenesis. Effectively, MOTS-c signals the body to make more, healthier mitochondria.
Exercise capacity
Aged mice given MOTS-c improved treadmill performance to levels approaching young controls. Human exercise-capacity trials are ongoing.
Metabolic flexibility
By activating AMPK and supporting fatty acid oxidation, MOTS-c improves the ability to switch between fuel sources — a key feature of metabolic health that declines with age.
Evidence summary
Lee C et al. (Cell Metabolism, 2015) is the founding paper — identified MOTS-c, demonstrated its presence in human plasma, and showed metabolic effects in mice including improved insulin sensitivity and reduced obesity on high-fat diet.
Reynolds JC et al. (Nature Communications, 2021) showed MOTS-c administration improved physical capacity and lifespan markers in aged mice.
Human clinical trial data is still early — pharmacokinetic studies and small Phase 1/2 trials in metabolic disease are ongoing. Off-label clinical use exceeds published large-trial evidence; physicians and patients should discuss this candidly.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
Typical clinical protocols use 5–10 mg subcutaneously, 2–3 times weekly, for 4–12-week courses.
Most protocols pair MOTS-c with lifestyle work — resistance training, zone-2 cardio, sleep optimization — because the peptide's pharmacology layers on top of exercise rather than replacing it.
Reassessment at 8–12 weeks with fasting glucose, HbA1c, lipid panel, and (when appropriate) DEXA composition.
Safety and contraindications
Generally well-tolerated. Mild injection-site reactions are the most common report. Serious adverse events have not been characterized in long-term human use.
Contraindications: pregnancy, active malignancy. Caution in active type 1 diabetes (insulin-sensitizing effects can interact). Discuss any insulin or sulfonylurea regimen with your physician.
Off-label use under physician supervision through a licensed 503A pharmacy. Not FDA-approved.
Who it's typically considered for
- Adults with prediabetes, metabolic syndrome, or central adiposity
- Women in perimenopause/menopause with new insulin-resistance findings on labs
- Patients training for endurance or strength who want mitochondrial-axis support
- Patients on or considering NAD+ protocols (MOTS-c and NAD+ both target mitochondrial health through different pathways)
Frequently asked questions
Is MOTS-c the same as NAD+?
No. Both support mitochondrial health but through different mechanisms. NAD+ is a coenzyme that fuels electron transport. MOTS-c is a peptide that activates AMPK and triggers mitochondrial biogenesis. They are often used together in longevity protocols.
Is MOTS-c FDA-approved?
No. MOTS-c is not FDA-approved for any indication. Compounded MOTS-c is prepared by licensed 503A pharmacies under physician prescription for off-label use.
How long until I see changes?
Energy and exercise capacity changes are often reported within 4–6 weeks. Lab changes (HbA1c, fasting insulin) are reassessed at 12 weeks. MOTS-c is a slow-acting metabolic peptide, not an acute energy peptide.
Does MOTS-c replace exercise?
No. MOTS-c is best thought of as augmenting the response to exercise, not replacing it. The published evidence consistently shows the peptide's effects are amplified when paired with physical activity.
Can I use MOTS-c with semaglutide or tirzepatide?
Yes — these are commonly layered. GLP-1s drive appetite and weight; MOTS-c targets mitochondrial function and insulin sensitivity. Your kindr physician monitors glucose carefully when combining.
Can women in menopause use MOTS-c?
Yes. Many of the metabolic shifts in perimenopause and menopause — declining insulin sensitivity, loss of metabolic flexibility, easier visceral fat accumulation — are exactly what MOTS-c is hypothesized to address.
Is MOTS-c safe long-term?
The long-term safety profile in healthy adults is not fully characterized in published trials. Shorter-course protocols with reassessment are the norm. Be skeptical of any provider who recommends indefinite MOTS-c use without periodic labs and benefit re-evaluation.
Sources
- Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism (2015). — www.cell.com/cell-metabolism/fulltext/S1550-4131(15)00098-7
- Reynolds JC et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications (2021). — www.nature.com/articles/s41467-020-20790-0
- Kim SJ et al. The mitochondrial-derived peptide MOTS-c — implications for metabolic disease. Frontiers in Endocrinology (2019). — www.frontiersin.org/articles/10.3389/fendo.2019.00582/full
- Merry TL et al. Mitochondrial-derived peptides in energy metabolism. American Journal of Physiology - Endocrinology and Metabolism (2020). — journals.physiology.org/doi/full/10.1152/ajpendo.00249.2020
Considering MOTS-c?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Start your longevity intake →Related peptides
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026
Last reviewed May 10, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.